Cancer Imaging With Fluorine-18-Labeled Choline Derivatives

Sandi A. Kwee, Timothy R. DeGrado, Jean Noel Talbot, Fabrice Gutman, Marc N. Coel

Research output: Contribution to journalReview article

94 Scopus citations

Abstract

The choline transporter and choline kinase enzyme frequently are overexpressed in malignancy. Therefore, positron-emitter-labeled compounds derived from choline have the potential to serve as oncologic probes for positron emission tomography. The fluorine-18 (18F)-labeled choline derivative fluorocholine (FCH) in particular has demonstrated potential utility for imaging of a variety of neoplasms, including those of the breast, prostate, liver, and brain. The pharmacokinetics of FCH and other choline tracers allow for whole-body imaging within minutes of injection while still achieving high tumor-to-background contrast in most organs, including the brain. These features, along with the possibility of imaging malignancies that have proved elusive with the use of 18F-fluorodeoxyglucose positron emission tomography support further clinical investigations of 18F-labeled choline tracers.

Original languageEnglish (US)
Pages (from-to)420-428
Number of pages9
JournalSeminars in Nuclear Medicine
Volume37
Issue number6
DOIs
StatePublished - Nov 2007

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Fingerprint Dive into the research topics of 'Cancer Imaging With Fluorine-18-Labeled Choline Derivatives'. Together they form a unique fingerprint.

  • Cite this